A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)

NCT00527904 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
239
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

POZEN